Glucagon-Like Peptide 1 - Analogs & derivatives
Research News and Information

Sunday, March 21, 2010

Beyond glycemic control: treating the entire type 2 diabetes disorder.

30 Aug 2009 The prevalence of type 2 diabetes mellitus, which is directly associated with overweight/obesity and increased cardiovascular disease risk, is projected to continue to increase during the next few decades. Traditionally, treatment has focused ... Read more...

Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.

26 Jul 2009 OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of liraglutide, a glucagon-like peptide 1 (GLP-1) analog for the treatment of type 2 diabetes mellitus. DATA SOURCES: A MEDLINE search (1966-May 2009) was conducted for ... Read more...

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.

21 Jul 2009 BACKGROUND: Glucagon-like peptide 1 (GLP1) analogues are promising new treatment options for patients with type 2 diabetes, but may have both potentially beneficial and harmful cardiovascular effects. This may also be the case for the analogues of ... Read more...

Latest indexed articles for 'Glucagon-Like Peptide 1 - Analogs & derivatives'

These are the very latest articles for this heading:

• Adverse events in diabetes drug trial. Oct 2009
• Beyond glycemic control: treating the entire type 2 diabetes disorder. 30 Aug 2009
• Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. 26 Jul 2009
• Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. 21 Jul 2009
• [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide] 29 Jun 2009
• GLP-1 analogues: a new therapeutic approach to prevent ductopenia in cholangiopathies? 29 Jun 2009
• Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. 19 Jun 2009
• The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. 16 Jun 2009
• Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. 7 Jun 2009
• GLP-1 receptor agonists for type 2 diabetes. 6 Jun 2009
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). 6 Jun 2009
• [Role and indication of GLP-1 analogues in the treatment of type 2 diabetes] Jun 2009
• Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. 29 Apr 2009
• Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies. 29 Apr 2009
• Minireview: Gut peptides: targets for antiobesity drug development? 14 Apr 2009
• [Incretin related agents for treatment of diabetes mellitus] 8 Apr 2009
• Potential of liraglutide in the treatment of patients with type 2 diabetes. 6 Apr 2009
• Diabetes treatment and measures of glycemia. 30 Mar 2009
• Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. 22 Mar 2009
• GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes. 16 Mar 2009

See a longer list of these articles.

Technical information about 'Glucagon-Like Peptide 1'

Definition: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.

Registry Number: 89750-14-1

Descriptor UI: D052216

Alternative terms: Glucagon-Like Peptide 1; Glucagon Like Peptide 1; Glucagon-Like Peptide-1; GLP-1; GLP 1;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Incretins;

Tree Number: D06.472.317.469.500.500;

History Note: 2006